About Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SymbolNASDAQ:LXRXPrevious Symbol: NASDAQ:LEXG
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$83.34 million
Price / Sales12.35
Price / CashN/A
Book Value$0.74 per share
Price / Book13.18
Return on Equity-111.68%
Return on Assets-34.02%
Frequently Asked Questions for Lexicon Pharmaceuticals (NASDAQ:LXRX)
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
How were Lexicon Pharmaceuticals' earnings last quarter?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.07. The biopharmaceutical company earned $26.94 million during the quarter, compared to the consensus estimate of $27.97 million. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The firm's revenue for the quarter was down 2.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.35) earnings per share. View Lexicon Pharmaceuticals' Earnings History.
Where is Lexicon Pharmaceuticals' stock going? Where will Lexicon Pharmaceuticals' stock price be in 2017?
5 Wall Street analysts have issued 12 month price targets for Lexicon Pharmaceuticals' shares. Their forecasts range from $21.00 to $39.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $28.75 in the next twelve months. View Analyst Ratings for Lexicon Pharmaceuticals.
What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (11/14/2017)
- 2. Cowen Inc analysts commented, "Xermelo’s US launch is off to a solid start with 2Q sales of $3.6MM just ahead of." (8/1/2017)
- 3. Wedbush analysts commented, "Even with FDA approval of LXRX's lead drug achieved, we still see several clinical and regulatory catalysts for LXRX over the coming months that could lift shares."In addition to the launch of XERMELO, we see several catalysts for LXRX, including data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17," (3/1/2017)
- 4. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)
Are investors shorting Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 13,435,509 shares, a decrease of 13.8% from the October 13th total of 15,586,182 shares. Based on an average trading volume of 742,164 shares, the days-to-cover ratio is presently 18.1 days. Currently, 13.1% of the company's stock are short sold.
Who are some of Lexicon Pharmaceuticals' key competitors?
Some companies that are related to Lexicon Pharmaceuticals include AnaptysBio (ANAB), Prothena Corporation PLC (PRTA), NovoCure Limited (NVCR), Acceleron Pharma (XLRN), Intercept Pharmaceuticals (ICPT), Ascendis Pharma A/S (ASND), MyoKardia (MYOK), Sangamo Therapeutics (SGMO), Clinigen Group PLC (CLIN), Radius Health (RDUS), Dynavax Technologies Corporation (DVAX), Ignyta (RXDX), Athenex (ATNX), Neuroderm Ltd (NDRM), Xencor (XNCR), Dermira (DERM), Acorda Therapeutics (ACOR) and REGENXBIO (RGNX).
Who are Lexicon Pharmaceuticals' key executives?
Lexicon Pharmaceuticals' management team includes the folowing people:
- Raymond Debbane, Independent Chairman of the Board (Age 62)
- Lonnel Coats, President, Chief Executive Officer, Director (Age 52)
- Jeffrey L. Wade J.D., Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs (Age 52)
- Pablo Lapuerta M.D., Executive Vice President, Chief Medical Officer (Age 53)
- Alan J. Main Ph.D., Executive Vice President - CMC and Supply Operations (Age 63)
- Alexander A. Santini, Executive Vice President, Chief Commercial Officer (Age 58)
- Praveen Tyle Ph.D., Executive Vice President - Research and Development (Age 57)
- James F. Tessmer, Vice President - Finance & Accounting (Age 57)
- Philippe J. Amouyal, Independent Director (Age 58)
- Samuel L. Barker Ph.D., Independent Director (Age 74)
Who owns Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Eagle Asset Management Inc. (2.68%), Pinnacle Associates Ltd. (0.85%), Kornitzer Capital Management Inc. KS (0.73%), Sector Gamma AS (0.70%), Columbus Circle Investors (0.40%) and Teachers Retirement System of The State of Kentucky (0.30%). Company insiders that own Lexicon Pharmaceuticals stock include James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.
Who sold Lexicon Pharmaceuticals stock? Who is selling Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Teachers Retirement System of The State of Kentucky, Bank of New York Mellon Corp, Eagle Asset Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for Lexicon Pharmaceuticals.
Who bought Lexicon Pharmaceuticals stock? Who is buying Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Pinnacle Associates Ltd., Tocqueville Asset Management L.P., Sector Gamma AS, Malaga Cove Capital LLC, GSA Capital Partners LLP, Fox Run Management L.L.C. and First Trust Advisors LP. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.
How do I buy Lexicon Pharmaceuticals stock?
Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lexicon Pharmaceuticals' stock price today?
One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $9.75.
How big of a company is Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals has a market capitalization of $1.01 billion and generates $83.34 million in revenue each year. The biopharmaceutical company earns $-141,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Lexicon Pharmaceuticals employs 168 workers across the globe.
How can I contact Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.
MarketBeat Community Rating for Lexicon Pharmaceuticals (LXRX)MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.80)|
|Consensus Price Target: ||$28.75 (194.87% upside)|
Consensus Price Target History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/17/2017||Needham & Company LLC||Reiterated Rating||Buy||$21.00||Medium|
|8/1/2017||Cowen Inc||Reiterated Rating||Hold||High|
|5/3/2017||HC Wainwright||Set Price Target||Buy||$27.00||High|
|3/7/2017||Citigroup Inc.||Boost Price Target||Buy||$24.00 -> $28.00||N/A|
|8/5/2016||Stifel Nicolaus||Boost Price Target||Buy||$25.00 -> $26.00||N/A|
|5/5/2016||J P Morgan Chase & Co||Reiterated Rating||Hold||$16.00||N/A|
Earnings History and Estimates Chart for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Earnings History by Quarter for Lexicon Pharmaceuticals (NASDAQ LXRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.36)||($0.29)||$27.97 million||$26.94 million||View||N/A|
|8/1/2017||Q2 2017||($0.45)||($0.33)||$18.34 million||$12.00 million||View||Listen|
|3/3/2017||Q4 2016||($0.51)||($0.31)||$15.56 million||$23.00 million||View||N/A|
|11/1/2016||Q316||($0.50)||($0.35)||$9.68 million||$27.70 million||View||N/A|
|8/4/2016||Q216||($0.40)||($0.37)||$12.36 million||$20.10 million||View||N/A|
|5/3/2016||Q1||($0.30)||($0.34)||$11.11 million||$12.50 million||View||N/A|
|3/1/2016||Q415||($0.38)||$0.76||$21.50 million||$127.30 million||View||N/A|
|11/6/2015||Q3||($0.36)||($0.34)||$0.44 million||$0.57 million||View||N/A|
|8/7/2015||Q215||($0.32)||($0.27)||$0.45 million||$376.00 million||View||N/A|
|4/29/2015||Q115||($0.04)||($0.04)||$1.10 million||$1.78 million||View||N/A|
|11/4/2014||Q3||($0.05)||($0.05)||$0.16 million||$0.40 million||View||N/A|
|8/7/2014||Q214||($0.05)||($0.05)||$0.13 million||$0.68 million||View||N/A|
|5/8/2014||Q114||($0.05)||($0.06)||$0.12 million||$277.00 million||View||N/A|
|2/28/2014||Q413||($0.06)||($0.03)||$1.66 million||$1.40 million||View||N/A|
|11/12/2013||Q3||($0.01)||($0.06)||$1.59 million||$0.24 million||View||Listen|
|2/21/2013||Q4 2012||($0.05)||($0.05)||$0.37 million||$0.22 million||View||N/A|
Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)
2017 EPS Consensus Estimate: ($1.70)
2018 EPS Consensus Estimate: ($1.18)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lexicon Pharmaceuticals (NASDAQ LXRX)
Insider Ownership Percentage: 5.77%
Insider Trades by Quarter for Lexicon Pharmaceuticals (NASDAQ LXRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/17/2017||Public Equities L.P. Invus||Director||Buy||180,727||$10.11||$1,827,149.97|| |
|11/15/2017||Lonnel Coats||CEO||Buy||10,000||$9.91||$99,100.00|| |
|11/14/2017||Jeffrey L Wade||EVP||Buy||2,000||$9.48||$18,960.00|| |
|11/14/2017||Public Equities L.P. Invus||Director||Buy||575,946||$9.64||$5,552,119.44|| |
|11/10/2017||Public Equities L.P. Invus||Director||Buy||145,680||$9.74||$1,418,923.20|| |
|9/15/2017||Lonnel Coats||Insider||Buy||30,000||$12.54||$376,200.00|| |
|9/15/2017||Sam L Barker||Director||Buy||1,000||$12.50||$12,500.00|| |
|6/6/2016||James F Tessmer||VP||Sell||1,500||$15.00||$22,500.00|| |
|5/23/2016||James F Tessmer||VP||Sell||6,000||$13.00||$78,000.00|| |
|12/12/2014||C.V. Invus||Director||Buy||150,000||$0.88||$132,000.00|| |
|12/10/2014||C.V. Invus||Director||Buy||315,896||$0.90||$284,306.40|| |
|11/26/2014||International S.C.A. Artal||Director||Buy||149,253,731||$1.01||$150,746,268.31|| |
|10/25/2013||Bryan A Kleinlein||CFO||Sell||227,626||$0.13||$29,591.38|| |
|10/9/2013||Bryan A Kleinlein||CFO||Sell||83,281||$0.19||$15,823.39|| |
|7/9/2013||Bryan A Kleinlein||CFO||Sell||88,235||$0.11||$9,705.85|| |
|6/27/2013||Alexander Richard Walsh||CEO||Sell||160,000||$0.13||$20,800.00|| |
|6/18/2013||Alexander Richard Walsh||CEO||Sell||220,000||$0.18||$39,600.00|| |
|6/7/2013||Alexander Richard Walsh||CEO||Sell||170,000||$0.19||$32,300.00|| |
|11/21/2012||Alexander Richard Walsh||CEO||Sell||23,700||$0.34||$8,058.00|| |
|10/23/2012||International S.C.A. Artal||Director||Buy||3,000,000||$2.25||$6,750,000.00|| |
|10/3/2012||Alexander Richard Walsh||CEO||Sell||25,000||$0.30||$7,500.00|| |
Latest Headlines for Lexicon Pharmaceuticals (NASDAQ LXRX)
|First Week Of July 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)|
www.thestreet.com - November 22 at 2:20 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Given Average Rating of "Hold" by Analysts|
www.americanbankingnews.com - November 19 at 3:44 AM
|$26.57 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter|
www.americanbankingnews.com - November 18 at 3:56 AM
|Insider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Buys 180,727 Shares of Stock|
www.americanbankingnews.com - November 17 at 10:26 PM
|Lexicon (LXRX) Looks Good: Stock Adds 7.6% in Session|
finance.yahoo.com - November 17 at 2:37 PM
|-$0.43 Earnings Per Share Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter|
www.americanbankingnews.com - November 16 at 5:30 PM
|Lexicon Pharmaceuticals, Inc. (LXRX) CEO Acquires $99,100.00 in Stock|
www.americanbankingnews.com - November 15 at 9:10 PM
|Insider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Purchases 145,680 Shares of Stock|
www.americanbankingnews.com - November 14 at 11:03 PM
|Lexicon Pharmaceuticals, Inc. (LXRX) Director Public Equities L.P. Invus Buys 575,946 Shares|
www.americanbankingnews.com - November 14 at 10:34 PM
|Jeffrey L. Wade Purchases 2,000 Shares of Lexicon Pharmaceuticals, Inc. (LXRX) Stock|
www.americanbankingnews.com - November 14 at 9:50 PM
|5 greater Houston-area companies make Deloitte's Technology Fast 500 - Houston Business Journal|
www.bizjournals.com - November 13 at 5:13 PM
|Lexicon Pharmaceuticals, Inc. (LXRX) Sees Significant Decrease in Short Interest|
www.americanbankingnews.com - November 12 at 5:34 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS|
www.americanbankingnews.com - November 9 at 7:48 PM
|ETFs with exposure to Lexicon Pharmaceuticals, Inc. : November 7, 2017|
finance.yahoo.com - November 9 at 2:38 AM
|Edited Transcript of LXRX earnings conference call or presentation 8-Nov-17 1:00pm GMT|
finance.yahoo.com - November 8 at 9:38 PM
|Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business Update|
finance.yahoo.com - November 8 at 4:28 PM
|Lexicon reports 3Q loss|
finance.yahoo.com - November 8 at 4:28 PM
|Lexicon Pharmaceuticals, Inc. (LXRX) Scheduled to Post Earnings on Wednesday|
www.americanbankingnews.com - November 3 at 8:26 PM
|Lexicon Pharmaceuticals To Host Third Quarter 2017 Financial Results Conference Call And Webcast On November 8, 2017|
finance.yahoo.com - November 3 at 4:09 PM
|First Week Of LXRX December 15th Options Trading|
www.thestreet.com - October 25 at 6:54 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - October 25 at 4:45 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Set to Announce Earnings on Monday|
www.americanbankingnews.com - October 23 at 10:02 AM
|Lexicon Pharmaceuticals Becomes Oversold (LXRX) - Nasdaq|
www.nasdaq.com - October 21 at 6:18 AM
|Breakfast Technical Briefing on Biotech Stocks -- BioCryst Pharma, Celgene, Juno Therapeutics, and Lexicon Pharma - PR Newswire (press release)|
www.prnewswire.com - October 18 at 6:49 AM
|ETFs with exposure to Lexicon Pharmaceuticals, Inc. : October 16, 2017|
finance.yahoo.com - October 16 at 7:58 PM
|News Flash: The FDA Just Approved a Breakthrough Diabetes Device|
finance.yahoo.com - October 16 at 5:26 AM
|FY2019 Earnings Estimate for Lexicon Pharmaceuticals, Inc. Issued By Wedbush (LXRX)|
www.americanbankingnews.com - October 9 at 7:58 AM
|Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017|
finance.yahoo.com - October 6 at 10:08 AM
|ETFs with exposure to Lexicon Pharmaceuticals, Inc. : October 5, 2017|
finance.yahoo.com - October 6 at 10:08 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Given Outperform Rating at Wedbush|
www.americanbankingnews.com - October 5 at 9:30 PM
|Will Insiders Be Tempted To Buy More LXRX At The New 52-Week Low?|
www.nasdaq.com - October 4 at 6:23 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Receives Average Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - September 30 at 4:50 AM
|Lexicon Pharma (LXRX) Commences Patient Dosing In Phase 1 Study Of LX9211 - StreetInsider.com|
www.streetinsider.com - September 29 at 11:59 PM
|Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211 - PR Newswire (press release)|
www.prnewswire.com - September 27 at 10:04 AM
|Lexicon Pharmaceuticals Offers Long-Term Value With New Product Launch - Seeking Alpha|
seekingalpha.com - September 27 at 10:04 AM
|Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211|
finance.yahoo.com - September 27 at 10:04 AM
|Critical Comparison: Lexicon Pharmaceuticals (LXRX) & uniQure N.V. (QURE)|
www.americanbankingnews.com - September 27 at 8:43 AM
| Analysts Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) Will Post Quarterly Sales of $33.98 Million|
www.americanbankingnews.com - September 21 at 5:12 AM
|Lexicon Pharma (LXRX) Granted European Commission Approval for XERMELO (Telotristat Ethyl) - StreetInsider.com|
www.streetinsider.com - September 20 at 5:40 AM
|Lexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $376200 of Shares - Nasdaq|
www.nasdaq.com - September 20 at 5:40 AM
|European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy|
finance.yahoo.com - September 20 at 5:40 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Earnings of -$0.35 Per Share|
www.americanbankingnews.com - September 19 at 4:26 PM
|Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 18 at 8:07 PM
|Lonnel Coats Buys 30,000 Shares of Lexicon Pharmaceuticals, Inc. (LXRX) Stock|
www.americanbankingnews.com - September 18 at 7:23 AM
|Lexicon Pharmaceuticals, Inc. (LXRX) Director Sam L. Barker Buys 1,000 Shares|
www.americanbankingnews.com - September 18 at 7:23 AM
|Lexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at Needham & Company LLC|
www.americanbankingnews.com - September 17 at 8:48 AM
|Lexicon Thumped Despite Favorable Data - Seeking Alpha|
seekingalpha.com - September 16 at 6:14 AM
|Slashing Fair Value Estimate on Lexicon Pharmaceuticals|
finance.yahoo.com - September 16 at 6:13 AM
|Why Lexicon Pharmaceuticals Is Down 11% Today|
www.fool.com - September 14 at 12:46 PM
|Lexicon Pharmaceuticals is Now Oversold (LXRX)|
www.nasdaq.com - September 14 at 7:24 AM
Lexicon Pharmaceuticals (NASDAQ LXRX) Chart for Thursday, November, 23, 2017